Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Advanced Donor Age Impairs Bone Marrow Cell Therapeutic Efficacy for Cardiac Disease.

Wang X, Takagawa J, Haddad DJ, Pinnamaneni K, Zhang Y, Sievers RE, Grossman W, Yeghiazarians Y, Springer ML.

J Tissue Sci Eng. 2011 Nov 18;S3. pii: 002.

2.

Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response.

Wang X, Takagawa J, Lam VC, Haddad DJ, Tobler DL, Mok PY, Zhang Y, Clifford BT, Pinnamaneni K, Saini SA, Su R, Bartel MJ, Sievers RE, Carbone L, Kogan S, Yeghiazarians Y, Hermiston M, Springer ML.

Sci Transl Med. 2011 Sep 14;3(100):100ra90. doi: 10.1126/scitranslmed.3002814.

3.

Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy.

Assmus B, Tonn T, Seeger FH, Yoon CH, Leistner D, Klotsche J, Schächinger V, Seifried E, Zeiher AM, Dimmeler S.

J Am Coll Cardiol. 2010 Mar 30;55(13):1385-94. doi: 10.1016/j.jacc.2009.10.059.

4.

eNOS overexpressing bone marrow cells are safe and effective in a porcine model of myocardial regeneration following acute myocardial infarction.

Ward MR, Connelly KA, Vijayaraghavan R, Vaags AK, Graham JJ, Foltz W, Hough MR, Stewart DJ, Dick A.

Cardiovasc Ther. 2013 Dec;31(6):e72-8. doi: 10.1111/1755-5922.12037.

PMID:
23837864
5.

Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.

Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy ResearchNetwork..

JAMA. 2011 Nov 16;306(19):2110-9. doi: 10.1001/jama.2011.1670.

6.

Timing of bone marrow cell delivery has minimal effects on cell viability and cardiac recovery after myocardial infarction.

Swijnenburg RJ, Govaert JA, van der Bogt KE, Pearl JI, Huang M, Stein W, Hoyt G, Vogel H, Contag CH, Robbins RC, Wu JC.

Circ Cardiovasc Imaging. 2010 Jan;3(1):77-85. doi: 10.1161/CIRCIMAGING.109.872085.

7.

Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease.

van Koppen A, Papazova DA, Oosterhuis NR, Gremmels H, Giles RH, Fledderus JO, Joles JA, Verhaar MC.

Stem Cell Res Ther. 2015 Apr 15;6:63. doi: 10.1186/s13287-015-0064-7.

8.

Myocardial injection of apelin-overexpressing bone marrow cells improves cardiac repair via upregulation of Sirt3 after myocardial infarction.

Li L, Zeng H, Hou X, He X, Chen JX.

PLoS One. 2013 Sep 6;8(9):e71041. doi: 10.1371/journal.pone.0071041.

9.

[Experimental study on rejection of allogeneic donor bone marrow cells in sensitized recipients].

Xu LH, Fang JP, Weng WJ, Xu HG, Ye QX.

Zhonghua Xue Ye Xue Za Zhi. 2011 Nov;32(11):734-8. Chinese.

PMID:
22339907
10.

Involvement of miR-34c in high glucose-insulted mesenchymal stem cells leads to inefficient therapeutic effect on myocardial infarction.

Kang HJ, Kang WS, Hong MH, Choe N, Kook H, Jeong HC, Kang J, Hur J, Jeong MH, Kim YS, Ahn Y.

Cell Signal. 2015 Nov;27(11):2241-51. doi: 10.1016/j.cellsig.2015.07.024.

PMID:
26232617
11.

Efficacy of donor splenocytes mixed with bone marrow cells for induction of tolerance in sublethally irradiated mice.

Hashimoto N, Narumi S, Itabashi Y, Hakamada K, Sasaki M.

Transpl Immunol. 2002 Jun;10(1):37-41.

PMID:
12182463
12.

Safety and efficacy of intracoronary hypoxia-preconditioned bone marrow mononuclear cell administration for acute myocardial infarction patients: The CHINA-AMI randomized controlled trial.

Hu X, Huang X, Yang Q, Wang L, Sun J, Zhan H, Lin J, Pu Z, Jiang J, Sun Y, Xiang M, Liu X, Xie X, Yu X, Chen Z, Tse HF, Zhang J, Wang J.

Int J Cardiol. 2015 Apr 1;184:446-51. doi: 10.1016/j.ijcard.2015.02.084.

13.

[Autologous bone marrow cell infusion therapy for liver cirrhosis--now and future].

Sakaida I.

Rinsho Byori. 2011 Dec;59(12):1092-8. Review. Japanese.

PMID:
22338911
14.

Loss of Sirt3 limits bone marrow cell-mediated angiogenesis and cardiac repair in post-myocardial infarction.

Zeng H, Li L, Chen JX.

PLoS One. 2014 Sep 5;9(9):e107011. doi: 10.1371/journal.pone.0107011.

15.

Preservation of myocardial structure is enhanced by pim-1 engineering of bone marrow cells.

Quijada P, Toko H, Fischer KM, Bailey B, Reilly P, Hunt KD, Gude NA, Avitabile D, Sussman MA.

Circ Res. 2012 Jun 22;111(1):77-86. doi: 10.1161/CIRCRESAHA.112.265207.

16.

Extracellular high mobility group box 1 plays a role in the effect of bone marrow mononuclear cell transplantation for heart failure.

Kaneko M, Shintani Y, Narita T, Ikebe C, Tano N, Yamahara K, Fukushima S, Coppen SR, Suzuki K.

PLoS One. 2013 Oct 18;8(10):e76908. doi: 10.1371/journal.pone.0076908.

17.

Micro-RNA-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease.

Xu Q, Seeger FH, Castillo J, Iekushi K, Boon RA, Farcas R, Manavski Y, Li YG, Assmus B, Zeiher AM, Dimmeler S.

J Am Coll Cardiol. 2012 Jun 5;59(23):2107-17. doi: 10.1016/j.jacc.2012.02.033.

18.

Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial.

Roncalli J, Mouquet F, Piot C, Trochu JN, Le Corvoisier P, Neuder Y, Le Tourneau T, Agostini D, Gaxotte V, Sportouch C, Galinier M, Crochet D, Teiger E, Richard MJ, Polge AS, Beregi JP, Manrique A, Carrie D, Susen S, Klein B, Parini A, Lamirault G, Croisille P, Rouard H, Bourin P, Nguyen JM, Delasalle B, Vanzetto G, Van Belle E, Lemarchand P.

Eur Heart J. 2011 Jul;32(14):1748-57. doi: 10.1093/eurheartj/ehq455.

19.

Sustained-release delivery of prostacyclin analogue enhances bone marrow-cell recruitment and yields functional benefits for acute myocardial infarction in mice.

Imanishi Y, Miyagawa S, Fukushima S, Ishimaru K, Sougawa N, Saito A, Sakai Y, Sawa Y.

PLoS One. 2013 Jul 19;8(7):e69302. doi: 10.1371/journal.pone.0069302.

20.

Platelet-derived growth factor-AB promotes the generation of adult bone marrow-derived cardiac myocytes.

Xaymardan M, Tang L, Zagreda L, Pallante B, Zheng J, Chazen JL, Chin A, Duignan I, Nahirney P, Rafii S, Mikawa T, Edelberg JM.

Circ Res. 2004 Mar 19;94(5):E39-45.

Supplemental Content

Support Center